Palisade BIO, Inc. insider trading

Every open-market purchase and sale by Palisade BIO, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $296,650 10 trades by 2 insiders 3 months later: median −28.1% (−32.0% vs S&P 500) Insider sales, 5 years $420,525 4 trades by 2 insiders 3 months later: median −12.2% (−19.4% vs S&P 500)

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Palisade BIO, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Palisade BIO, Inc.’s insiders pay?

From January 4, 2010 to October 5, 2026, 13 insiders reported 25 open-market purchases and 34 sales not made under a pre-set plan in Palisade BIO, Inc. Twelve months after each purchase was reported, the shares were −81.9% against the S&P 500 on average (median −81.9%), over 1 purchase with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 28, 2017 into $3,889 by November 2, 2026, −9.4% a year. It held shares 10% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $14,301 (+3.8% a year), and held throughout $37,260 (+14.7%).

Copying Palisade BIO, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Palisade BIO, Inc.'s insiders from March 28, 2017, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 10% of the time.

Palisade BIO, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Johe Karl	Chief Scientific Officer	0	—	—	30	—	November 16, 2015
Daly Richard J	Chief Executive Officer	7	—	—	0	—	May 18, 2017
Baltera Robert JR.	Director	3	—	—	0	—	July 10, 2026
Finley John David	CEO, CFO	2	—	—	1	—	July 8, 2026
Garr Richard	CEO	1	—	—	2	—	April 23, 2014
Hallam Thomas	Chief Executive Officer	3	—	—	0	—	August 18, 2022
Lloyd Jones Jonathan Brian	Chief Financial Officer	2	−81.9% (1)	0%	0	—	March 27, 2017
Oldaker William Clyde	Director	2	—	—	0	—	May 7, 2014
Williams Donald Allen	Director	2	—	—	0	—	October 5, 2026
Conron John	Chief Financial Officer	1	—	—	0	—	January 4, 2010
Dawson Michael John	Chief Medical Officer	1	—	—	0	—	March 31, 2022
Jones Mitchell Lawrence	Chief Medical Officer	0	—	—	1	—	July 8, 2026
Trenschel Robert J.	Director	1	—	—	0	—	September 13, 2021

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Palisade BIO, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Palisade BIO, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −82.6% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
March 31, 2017	2 buying	+6.6%	−82.6%	−82.4%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Palisade BIO, Inc. · Funds · Politicians